COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update

Ian A. Yang, Juliet L. Brown, Johnson George, Sue Jenkins, Christine F. McDonald, Vanessa M. McDonald, Kirsten Phillips, Brian J. Smith, Nicholas A. Zwar, Eli Dabscheck

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and chronic airflow limitation, and is associated with exacerbations and comorbidities. Advances in the management of COPD are updated quarterly in the national COPD guidelines, the COPD-X plan, published by Lung Foundation Australia in conjunction with the Thoracic Society of Australia and New Zealand and available at http://copdx.org.au. Main recommendations: ∙ Spirometry detects persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) and must be used to confirm the diagnosis. ∙ Non-pharmacological and pharmacological therapies should be considered as they optimise function (ie, improve symptoms and quality of life) and prevent deterioration (ie, prevent exacerbations and reduce decline). ∙ Pulmonary rehabilitation and regular exercise are highly beneficial and should be provided to all symptomatic COPD patients. ∙ Short- and long-acting inhaled bronchodilators and, in more severe disease, anti-inflammatory agents (inhaled cortico-steroids) should be considered in a stepwise approach. ∙ Given the wide range of inhaler devices available, inhaler technique and adherence should be checked regularly. ∙ Smoking cessation is essential, and influenza and pneumococcal vaccinations reduce the risk of exacerbations. ∙ A plan of care should be developed with the multidisciplinary team. COPD action plans reduce hospitalisations and are recommended as part of COPD self-management. ∙ Exacerbations should be managed promptly with bronchodilators, corticosteroids and antibiotics as appropriate to prevent hospital admission and delay COPD progression. ∙ Comorbidities of COPD require identification and appropriate management. ∙ Supportive, palliative and end-of-life care are beneficial for patients with advanced disease. ∙ Education of patients, carers and clinicians, and a strong partnership between primary and tertiary care, facilitate evidence-based management of COPD. Changes in management as result of the guideline: Spirometry remains the gold standard for diagnosing airflow obstruction and COPD. Non-pharmacological and pharmacological treatment should be used in a stepwise fashion to control symptoms and reduce exacerbation risk.

Original languageEnglish
Pages (from-to)436-442
Number of pages7
JournalMedical Journal of Australia
Volume207
Issue number10
DOIs
Publication statusPublished - 20 Nov 2017
Externally publishedYes

Fingerprint

New Zealand
Chronic Obstructive Pulmonary Disease
Guidelines
Bronchodilator Agents
Nebulizers and Vaporizers
Spirometry
Comorbidity
Pharmacology
Exercise Therapy
Lung
Terminal Care
Smoking Cessation
Patient Education
Tertiary Healthcare
Self Care
Disease Management
Human Influenza
Caregivers
Disease Progression
Primary Health Care

Cite this

Yang, I. A., Brown, J. L., George, J., Jenkins, S., McDonald, C. F., McDonald, V. M., ... Dabscheck, E. (2017). COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Medical Journal of Australia, 207(10), 436-442. https://doi.org/10.5694/mja17.00686
Yang, Ian A. ; Brown, Juliet L. ; George, Johnson ; Jenkins, Sue ; McDonald, Christine F. ; McDonald, Vanessa M. ; Phillips, Kirsten ; Smith, Brian J. ; Zwar, Nicholas A. ; Dabscheck, Eli. / COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease : 2017 update. In: Medical Journal of Australia. 2017 ; Vol. 207, No. 10. pp. 436-442.
@article{527fe6fdfa3043dd99a2b8cd928ca717,
title = "COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update",
abstract = "Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and chronic airflow limitation, and is associated with exacerbations and comorbidities. Advances in the management of COPD are updated quarterly in the national COPD guidelines, the COPD-X plan, published by Lung Foundation Australia in conjunction with the Thoracic Society of Australia and New Zealand and available at http://copdx.org.au. Main recommendations: ∙ Spirometry detects persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) and must be used to confirm the diagnosis. ∙ Non-pharmacological and pharmacological therapies should be considered as they optimise function (ie, improve symptoms and quality of life) and prevent deterioration (ie, prevent exacerbations and reduce decline). ∙ Pulmonary rehabilitation and regular exercise are highly beneficial and should be provided to all symptomatic COPD patients. ∙ Short- and long-acting inhaled bronchodilators and, in more severe disease, anti-inflammatory agents (inhaled cortico-steroids) should be considered in a stepwise approach. ∙ Given the wide range of inhaler devices available, inhaler technique and adherence should be checked regularly. ∙ Smoking cessation is essential, and influenza and pneumococcal vaccinations reduce the risk of exacerbations. ∙ A plan of care should be developed with the multidisciplinary team. COPD action plans reduce hospitalisations and are recommended as part of COPD self-management. ∙ Exacerbations should be managed promptly with bronchodilators, corticosteroids and antibiotics as appropriate to prevent hospital admission and delay COPD progression. ∙ Comorbidities of COPD require identification and appropriate management. ∙ Supportive, palliative and end-of-life care are beneficial for patients with advanced disease. ∙ Education of patients, carers and clinicians, and a strong partnership between primary and tertiary care, facilitate evidence-based management of COPD. Changes in management as result of the guideline: Spirometry remains the gold standard for diagnosing airflow obstruction and COPD. Non-pharmacological and pharmacological treatment should be used in a stepwise fashion to control symptoms and reduce exacerbation risk.",
author = "Yang, {Ian A.} and Brown, {Juliet L.} and Johnson George and Sue Jenkins and McDonald, {Christine F.} and McDonald, {Vanessa M.} and Kirsten Phillips and Smith, {Brian J.} and Zwar, {Nicholas A.} and Eli Dabscheck",
year = "2017",
month = "11",
day = "20",
doi = "10.5694/mja17.00686",
language = "English",
volume = "207",
pages = "436--442",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AUSTRALASIAN MED PUBL CO LTD",
number = "10",

}

Yang, IA, Brown, JL, George, J, Jenkins, S, McDonald, CF, McDonald, VM, Phillips, K, Smith, BJ, Zwar, NA & Dabscheck, E 2017, 'COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update' Medical Journal of Australia, vol. 207, no. 10, pp. 436-442. https://doi.org/10.5694/mja17.00686

COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease : 2017 update. / Yang, Ian A.; Brown, Juliet L.; George, Johnson; Jenkins, Sue; McDonald, Christine F.; McDonald, Vanessa M.; Phillips, Kirsten; Smith, Brian J.; Zwar, Nicholas A.; Dabscheck, Eli.

In: Medical Journal of Australia, Vol. 207, No. 10, 20.11.2017, p. 436-442.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease

T2 - 2017 update

AU - Yang, Ian A.

AU - Brown, Juliet L.

AU - George, Johnson

AU - Jenkins, Sue

AU - McDonald, Christine F.

AU - McDonald, Vanessa M.

AU - Phillips, Kirsten

AU - Smith, Brian J.

AU - Zwar, Nicholas A.

AU - Dabscheck, Eli

PY - 2017/11/20

Y1 - 2017/11/20

N2 - Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and chronic airflow limitation, and is associated with exacerbations and comorbidities. Advances in the management of COPD are updated quarterly in the national COPD guidelines, the COPD-X plan, published by Lung Foundation Australia in conjunction with the Thoracic Society of Australia and New Zealand and available at http://copdx.org.au. Main recommendations: ∙ Spirometry detects persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) and must be used to confirm the diagnosis. ∙ Non-pharmacological and pharmacological therapies should be considered as they optimise function (ie, improve symptoms and quality of life) and prevent deterioration (ie, prevent exacerbations and reduce decline). ∙ Pulmonary rehabilitation and regular exercise are highly beneficial and should be provided to all symptomatic COPD patients. ∙ Short- and long-acting inhaled bronchodilators and, in more severe disease, anti-inflammatory agents (inhaled cortico-steroids) should be considered in a stepwise approach. ∙ Given the wide range of inhaler devices available, inhaler technique and adherence should be checked regularly. ∙ Smoking cessation is essential, and influenza and pneumococcal vaccinations reduce the risk of exacerbations. ∙ A plan of care should be developed with the multidisciplinary team. COPD action plans reduce hospitalisations and are recommended as part of COPD self-management. ∙ Exacerbations should be managed promptly with bronchodilators, corticosteroids and antibiotics as appropriate to prevent hospital admission and delay COPD progression. ∙ Comorbidities of COPD require identification and appropriate management. ∙ Supportive, palliative and end-of-life care are beneficial for patients with advanced disease. ∙ Education of patients, carers and clinicians, and a strong partnership between primary and tertiary care, facilitate evidence-based management of COPD. Changes in management as result of the guideline: Spirometry remains the gold standard for diagnosing airflow obstruction and COPD. Non-pharmacological and pharmacological treatment should be used in a stepwise fashion to control symptoms and reduce exacerbation risk.

AB - Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and chronic airflow limitation, and is associated with exacerbations and comorbidities. Advances in the management of COPD are updated quarterly in the national COPD guidelines, the COPD-X plan, published by Lung Foundation Australia in conjunction with the Thoracic Society of Australia and New Zealand and available at http://copdx.org.au. Main recommendations: ∙ Spirometry detects persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.7) and must be used to confirm the diagnosis. ∙ Non-pharmacological and pharmacological therapies should be considered as they optimise function (ie, improve symptoms and quality of life) and prevent deterioration (ie, prevent exacerbations and reduce decline). ∙ Pulmonary rehabilitation and regular exercise are highly beneficial and should be provided to all symptomatic COPD patients. ∙ Short- and long-acting inhaled bronchodilators and, in more severe disease, anti-inflammatory agents (inhaled cortico-steroids) should be considered in a stepwise approach. ∙ Given the wide range of inhaler devices available, inhaler technique and adherence should be checked regularly. ∙ Smoking cessation is essential, and influenza and pneumococcal vaccinations reduce the risk of exacerbations. ∙ A plan of care should be developed with the multidisciplinary team. COPD action plans reduce hospitalisations and are recommended as part of COPD self-management. ∙ Exacerbations should be managed promptly with bronchodilators, corticosteroids and antibiotics as appropriate to prevent hospital admission and delay COPD progression. ∙ Comorbidities of COPD require identification and appropriate management. ∙ Supportive, palliative and end-of-life care are beneficial for patients with advanced disease. ∙ Education of patients, carers and clinicians, and a strong partnership between primary and tertiary care, facilitate evidence-based management of COPD. Changes in management as result of the guideline: Spirometry remains the gold standard for diagnosing airflow obstruction and COPD. Non-pharmacological and pharmacological treatment should be used in a stepwise fashion to control symptoms and reduce exacerbation risk.

UR - http://www.scopus.com/inward/record.url?scp=85034966972&partnerID=8YFLogxK

U2 - 10.5694/mja17.00686

DO - 10.5694/mja17.00686

M3 - Article

VL - 207

SP - 436

EP - 442

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 10

ER -